Company
Telos Biotech
Overcoming The Biggest Barriers in Cell Therapy: Senescence and Exhaustion
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Headquarters
- New York, United States
- Customers
- any cell therapy manufacturing process
- Legal name
- Telos Biotech
Claim, correct or request removal
Record updated 28 September 2026
About
Cell therapies hold promise in a wide range of diseases. However, several challenges limit their therapeutic potential, including development of critically short telomeres. During the cell therapy manufacturing process, normal human cells are forced to expand rapidly, resulting in significant telomere shortening. This effect may reduce a cell's lifespan and limits the long-term favorable outcome for patients. Telos Biotech has developed an approach that is designed to rapidly and safely lengthen the shortest telomeres, helping to ensure that engineered cells are therapeutically robust: Telovance™.
Funding snapshot
- Total raised
- $1.4MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $725K2025-12-01
Funding rounds
- Round, 2025
- $725K2025-12-01, SEC form D sold, 4 investors
- Round, 2019
- $700K2019-12-23, SEC form D sold, 1 investor
Products
- Other
- Telovance™
Loading relationship preview